introduction
Treatment of malignant lymphomas consists of multiple cycles of polychemo-, immuno-or radiation-therapy, hematopoetic stem cell transplantation (HSCT) or a combination thereof. The disease, its treatment and the extended hospital stays lead to reduced quality of life (QOL) due to increased immobility, physical deconditioning [1] apparent as muscle atrophy [2] , loss of balance control [3] , instable gait and enhanced incidence of falls. Additionally, ∼50% of lymphoma patients suffer from therapy-induced peripheral neuropathy (PNP), a decisive limiting factor for therapy [4] [5] [6] . PNP is a highly prevalent sideeffect associated with impaired balance control, an increased risk of falls [7] , further increasing immobility. No randomized, controlled trial (RCT) has evaluated the effects of exercise on the side-effects of PNP. Studies in healthy adults e.g. revealed that sensorimotor training (SMT) can induce sensory effects [8] , but it has never been studied in cancer patients. In our prospective RCT, we assessed the effects of exercise, especially SMT, in lymphoma patients during therapy. We hypothesized that our exercise program reduces therapy-induced side-effects and improves patients' physical condition, neuromuscular function, balance control and cardiovascular fitness, overall improving QOL.
patients and methods
Our prospective, single-center, two armed, open RCT (ratio 1:1) was approved by the Freiburg University Medical Center institutional review board and ethics commission. All patients gave written informed consent for treatment and prospective data collection in accordance with the Declaration of Helsinki.
patient characteristics
Between May 2008 and July 2011, 365 patients with malignant lymphoma, scheduled for therapy, aged ≥18 years were screened for further inclusion criteria: Karnofsky performance status >60 and an indication for chemotherapy (see S1a).
Every patient passed the institutional lymphoma board, a physical examination, stress electrocardiogram, echocardiography, pulmonary function and blood tests to rule out possible exclusion criteria [instable osteolysis, severe acute infections, severe cardial-and pulmonary impairments (S1b)] or restrictions for physical activity. One hundred eighty-six eligible patients were informed and asked to participate. While 125 declined, 61 signed the written informed consent and were randomized (CONSORT supplementary Figure S1 , available at Annals of Oncology online). All patients received standard clinical care including physiotherapy. Only the intervention group (IG) carried out the training intervention.
training intervention
The IG trained twice a week, over 36 weeks, supervised by certified sport-or physiotherapists. Training was only interrupted for 24 h after administration of chemotherapy. Protocols were based on previous research [9] [10] [11] [12] and designed for all phases of cancer therapy. Each ∼1-h session consisted of: (i) Aerobic endurance training: Cardiovascular activation on a bicycle-dynamometer (60%-70% max heart rate), 10-to 30-min walk on a treadmill or bicycle dynamometer (at 70%-80% max heart rate) at the end of the session [10] .
(ii) Sensorimotor training: Four postural stabilization tasks, progressively increasing task difficulty as well as surface instability, carried out in three sets. Each set was carried out at 20-s intervals, allowing a 20-s rest between each set and 1 min between exercises to avoid fatigue [9] . (iii) Strength training: Four resistance exercises carried out for 1 min at maximum force, for inpatients substituted with a Thera-Band™ (Dornburn, Germany) [13] .
To ensure patients safety, training was supervised (one-on-one), blood parameters monitored before each training session, blood pressure and heart rate measured before, during and after training (see S1c).
measurements
Primary end point was QOL. Secondary end points were movement coordination, endurance, strength and therapy-induced side-effects.
All participants were evaluated at four time points: prior to chemotherapy (within the first cycle of therapy at the latest) (T0), after 12 (T1), 24 (T2) and 36 (T3) weeks (supplementary Table S1 , available at Annals of Oncology online), including: primary end point. Quality of Life assessed with the EORTC QLQ-C30 questionnaire [14] . secondary end points.
(i) PNP: Peripheral deep sensitivity was evaluated by a tuning fork with a graduating scale from 0 (no sensitivity) to 8 (highest sensitivity). Pathological values are 0-5 for patients <60 years and 0-4 for patients ≥60 years [15, 16] . Measurement was carried out blinded, bilaterally, at the metatarsophalangeal and malleolus medialis, twice. Patients never receiving potentially neurotoxic medication, with a reduction of neurotoxic medication due to PNP, with PNPs of other derivation or due to prior therapy (PD/relapse), were monitored but excluded in the count.
(ii) Activity level: Both groups were asked to document any activities (type of exercise, duration in hour/week and frequency) outside the intervention in a training log-book. Activities were subsequently transferred into the metabolic equivalent (MET) [17] . The cumulative sway path of all sets was averaged to minimize any learning effects. Measurements were regarded as failed attempts whenever patients needed support to maintain balance.
original articles Annals of Oncology (i) Balance control following mechanical perturbation: On the Posturomed™ (Pullenreuth, Germany), an oscillating, 2D platform, allowing translational movements in the transversal plane, a perturbation impulse was applied by releasing the platform attached to a magnet (2.5 cm away) unexpectedly. Tasks were carried out in five sets at 10-s intervals.
Analysis included cumulative sway paths, peak-to-peak amplitudes, the time needed to regain balance control and the number of failed attempts, leading to average values from all five attempts (S1d).
(i) Incremental step test to determine lactic threshold: Simultaneously to a stress ECG, starting at 25 watts, increasing by 25 watts every 3 min. We evaluated lactate levels, heart frequency, watts, maximum performance levels [maximum power (watts), in relation to bodyweight: p max/kg] and the individual anaerobic threshold (IAS).
(ii) Side-effects monitored: Subjective Global Assessment questionnaire (SGA) [18] was used to monitor the nutritional status. Further, 22 clinical signs were queried via a checklist as well as the level of anxiety and depression (Hospital Anxiety and Depression Scale) and cognitive impairment (Fragebogen Erlebter Defizite der Aufmerksamkeit), at each time point (S1d).
sample size
In order to demonstrate a intergroup difference for the primary end point QOL with a power of 80% at a two-sided level of α = 5%, assuming a relevant difference of 10 points and a standard deviation of 24 points, 92 patients per group are necessary. In order to account for dropouts and for the application of nonparametric tests, it was planned to randomize a total of 240 patients, assuming that 60-120 patients could be enrolled per year.
Owing to low recruitment, an unscheduled interim analysis was carried out after 3 years with 61 patients randomized. The primary end point did not reveal significant group differences; however, the physiological secondary end points showed highly relevant and significant results. With the ongoing recruitment velocity, it seemed unrealistic to achieve the planned sample size within the course of the study. At this point, we considered physiological parameters much more relevant to evaluate the intervention than QOL; hence, the study was stopped early. randomization Randomization was carried out by an independent randomization office (WiSP GmbH, Langenfeld, Germany).
statistical analysis
For continuous outcomes, changes from baseline to T1, T2 and T3 were computed. Intergroup differences were analyzed using Wilcoxon's twosample test. For parameters of particular interest, the test was used for additional intragroup comparisons. Categorical variables were analyzed using Fisher's exact test. The incidence of PNP was computed at each time point. The average of these values is reported.
The amount of missing data was distributed relatively fair between groups (see Consort). Intention to treat strategies for substituting missing values aim to reach conservative results. However, especially for the physiological parameters, we did not want to underestimate the effect size; hence, missing data due to patient's dropout were excluded from the analysis. In the balance tasks, missing values resulting from failed attempts were replaced by values sufficiently high to be recognized as extreme (maximum or minimum).
All results presented refer to the intention to treat analysis analysis and intergroup comparison unless specified otherwise. Following previous research, exercise should be carried out at least twice a week [9] . An additional per protocol analysis excludes patients participating only once a week (25% adherence).
Level of significance was set to P < 0.05, two-sided. No alpha adjustment was made. Analyses were carried out using SAS, version 9.2 and SPSS statistics 21.
results
Overall 61 patients were randomly assigned to the IG (N = 30) or CG (N = 31) ( Table 1 and supplementary Table S2 , available at Annals of Oncology online). Patient characteristics at baseline (Table 2 ) and during the study regarding therapy revealed no significant intergroup differences (Table 3) . Average compliance for all time points and all interventions was 65% (highest for SMT, lowest for strength, highest in stationary phases, lowest after completion of therapy).
primary end point QOL. A significant intergroup difference (Δ T1-T0; P = 0.03) could be detected for health-related QOL within the first 12 weeks, though not after 36 weeks. Additionally, constipation (Δ T2-T0; P = 0.03), diarrhea (Δ T2-T0: P = 0.04), emotional function (Δ T3-T2; P = 0.007) and financial problems (Δ T3-T2; P = 0.04) differed between the groups at various time-points. The IG (intragroup) significantly improved their QOL (Δ T3-T0; P = 0.03) (supplementary Figure S2 , available at Annals of Oncology online), constipation (Δ T3-T0; P = 0.05), diarrhea (Δ T3-T0; P = 0.02) and a tendency regarding pain (Δ T3-T0; P = 0.06), while the CG showed no changes.
secondary end points (i) PNP: Peripheral deep sensitivity: The average incidence was lower in the IG (12%) than in the CG (27%) (Δ T3-T0; P = 0.07). Additionally, the symptom diminished in 87.5% of the IG, while no patient (0%) in CG showed reduced PNP, once developed (P < 0.001). At T3, the total number of patients suffering from reduced peripheral deep sensitivity was significantly lower in the IG (P = 0.002) (supplementary Figure S3A and B, available at Annals of Oncology online). There were no significant intergroup differences concerning neurotoxic medication and therapy. PNP was symmetrical in all but two patients at T2, thus counting the neuropathic value.
(ii) Activity level: (MET hour/week) Activity levels not only differed significantly among the groups due to the intervention but also outside the intervention (Δ T3-T0; P = 0.03). The IG increased their activity level by 2.5MET/week (median), while the CG deteriorated (supplementary Figure S4 , available at Annals of Oncology online). (iii) Balance control on static surface: a) Cumulative sway paths: In the monopedal stance, the IG reduced sway paths by an average of 18%, while the CG declined (Δ T3-T0; P = 0.04) (supplementary Figure S5A , available at Annals of Oncology online). Neither the static bipedal blind task nor the baseline comparison differed significantly. b) Failed attempts: (supplementary Figure S5B , available at Annals of Oncology online). In the monopedal task, we found significant intergroup differences at all timeAnnals of Oncology original articles b) Failed attempts: The monopedal perturbed task also revealed significant differences (Δ T3-T0 ;P = 0.002) at all measuring points. The IG fulfilled all tasks (100%). The CG progressively declined (to only 40% succeeding) throughout the study. No significant differences were detected in the bipedal tasks. c) Time necessary to regain balance (bringing the oscillating force plate to a halt): The IG improved time by 0.32 s, while the CG gained 0.29 s compared with baseline (Δ T3-T0 ; P = 0.007). (vi) Incremental step test to determine lactic threshold: The IG (intragroup) presented a reduction in maximum lactate (Δ T2-T0 ; P = 0.03) simultaneously raising their performance level (Δ T3-T0 ; P = 0.05). No intergroup changes were shown for T3-T0, IAS or IAS in relation to bodyweight. (vii) Amount of side-effects was reduced in the IG in relation to baseline (Δ T3-T0 ; P = 0.043).
In the per protocol analysis, results were equal or better. discussion Consistent with our hypothesis, patients benefited from our specific exercise program throughout all phases of therapy and were able to improve their QOL.
No study has addressed the distinct impact in QOL due to PNP and loss of balance control. Only one study has assessed exercise in lymphoma patients [10] . The toxic components of chemotherapy can cause functional and structural damage to nerve fibers. The axonal damage caused leads to reduced nerveconduction velocity and excitability [6] . In consequence, patients experience reduced sensitivity, pain, increased loss of balance control and risk of falling [19] . This further diminishes QOL and causes treatment delays, dose reductions or discontinuation of therapy, affecting outcome and survival [5] . Management remains challenging, as treatment strategies to limit or prevent PNP are insufficient [20] . Balance training has shown beneficial effects e.g. in diabetics with PNP [21] . We found exercise, especially SMT, not only improved balance control, but seemingly also influences the incidence and recovery of PNP. The underlying mechanisms must still be elucidated. One possibility could lie in the regenerative effect of SMT on nerve fibers [22] . A further possibility is attributed to the nervous system's plasticity: (i) an increase in the density of receptors, (ii) activating deafferented neurons [23] by increasing the metabolism, (iii) lowering the threshold for excitability [24] or (iv) inducing supraspinal learning effects [22] . Twelve-week intervals leave room for regeneration and possible functional adaptions of the peripheral nerves. Short-term effects should also be considered in future studies.
Exercise further contributes to QOL and can counteract additional risk factors. Studies in healthy adults have revealed that SMT can lead to functional adaptations of the neuromuscular system [8] regenerate neuromuscular structures, reduce reflex excitability, improve balance and diminish the prevalence of falls [22] . In line with these findings, in the perturbed monopedal stance, simulating stumbling, 54% of the CG patients were unable to maintain balance once therapy started and would have fallen, while the IG remained stable at all times. These positive effects are selectively associated with SMT and cannot be achieved with endurance or strength training alone [25] . The impact for our patients is reflected in the significant correlation with their QOL and an increase in physical activity (MET). Previous arguments let us conclude that possibly balance training, improving balance control, peripheral deep sensitivity and gait, contributes to an increased mobility (2.5MET/week-intervention excluded). With diagnosis, the CG carried out no exercise between the first two time-points and still only 3.5MET/week after completion of therapy. Underlying mechanisms remain to be investigated. Correlations (r = −0.40) (S2b) between endurance parameters and fatigue suggest that endurance training can affect fatigue.
Strength of our trial includes being the first RCT addressing balance control and PNP in cancer patients. It covers all phases of therapy, entails low-intensity exercises showing a large impact, no adverse events and its effects on outcomes are statistically and clinically meaningful; it also provides a comprehensive assessment of important outcomes with validated measures.
Yet, there are potential limitations: low recruitment and compliance due to the long duration, large catchment area and the single-center design. Interestingly, recruitment was similarly low in the comparable RCT on exercise in lymphoma patients (1306 screened/474 eligible/122 assessed) [10] . Sample-size suggests underpowerment but the highly significant physiological parameters were considered more relevant for patients' outcome; hence, the study was stopped early.
Furthermore, the study design was challenging, as there were no comparable references in hematology or oncology. Tasks had to be feasible for patients exhibiting very different performance levels, phases of therapy and age (range 19-75 years). This resulted in additional failed attempts rather than high sway paths. Furthermore, the time points had to target as many parameters as possible but simultaneously keep the burden low for patients. Resistance exercises had to be substituted with a Thera-Band™ for inpatients. This complicated data acquisition and revealed no viable results. Regarding physical activity, patients were only asked to report on additional exercises, not taking daily physical activities into account. In future, a questionnaire assessing physical activity could be useful.
In line with the gender-distribution of the disease, more men than women were recruited. As they are distributed evenly in both groups, bias should be small but cannot be excluded.
In summary, we provide evidence that exercise improves balance control and reduces side-effects of PNP, acknowledging these as substantial factors for QOL. Together with physical functioning, they are decisive factors for patients to receive their planned therapy regime, optimizing cancer control. Exercise, especially SMT, should therefore be implemented in the standard clinical care of cancer patients. Additional research on the impact of these findings for primary prevention, rehabilitation and further tumor entities is necessary.
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